UFP Technologies (UFPT)
Medical products company UFP Technologies Inc (NASDAQ:UFPT) is set to report its earnings this Tuesday after market hours. Here’s what to look for as the anticipation builds.
Last quarter, UFP Technologies exceeded analysts’ revenue expectations, posting revenues of $154.6 million, representing a year-on-year increase of 6.5%. It was a robust quarter for the company, with earnings per share (EPS) also surpassing analyst forecasts.
Market Expectations Ahead of Earnings
This quarter, analysts expect UFP Technologies to achieve a revenue growth of 3.5% year-on-year, a significant slowdown compared to the 41.9% growth from the same quarter last year. Nevertheless, the consistent reaffirmation of estimates by analysts over the past month indicates a stable outlook for the company heading into earnings.
UFP Technologies has a reputation for meeting Wall Street’s revenue estimates, which adds to the anticipation surrounding its upcoming report.
Industry Comparisons
When comparing UFP Technologies to its peers in the drug development inputs & services sector, recent reports give investors a glimpse of the potential performance. For instance, Medpace reported a year-on-year revenue growth of 32%, beating estimates by 3.3%, while West Pharmaceutical Services saw a 7.5% increase, surpassing projections by 1.5%. Despite these positive results, Medpace’s stock fell 15.9% following the announcement, while West Pharmaceutical Services gained 1.8%.
The economic landscape in 2025 has been marked by debates over tariffs and corporate tax cuts, creating a cloud of uncertainty. While some stocks in the drug development inputs & services sector have shown resilience, the overall group has underperformed, with an average decline of 3.4% in share prices over the last month. UFP Technologies itself is down 6.2% during that same period.
Analyst Sentiment and Price Target
Heading into the earnings report, the average analyst price target for UFP Technologies stands at $329.50, compared to its current share price of $231.69. This discrepancy highlights the potential upside as investors await the financial results.
For those interested in further insights, you can explore our full analysis on Inside Ticker, including a closer look at Medpace’s results and West Pharmaceutical Services.